Company intelligence / Profile preview
miRecule
Gaithersburg, Maryland, United Statesmirecule.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Preclinical
01
Overview
miRecule is developing RNA therapeutics for cancer and muscular dystrophy. Their lead candidate MC-30 for head and neck cancer has shown better tumor shrinkage and longer responses compared to standard of care in preclinical research. The company aims to file an IND application for this program in 2025.
- Therapeutic areas
- OncologyNeurology
- Modalities
- RNA therapeuticsAntibody-RNA conjugates (ARC)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on miRecule.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miRecule.